Zacks upgrades Bristol Myers Squibb stock to Strong Buy
Zacks has upgraded Bristol Myers Squibb (BMY) stock to a "Strong Buy," raising its fiscal 2027 earnings-per-share estimate to USD 6.24. This upgrade follows strong second-quarter 2026 performance with revenues of USD 12.97 billion and EPS of USD 2.04, exceeding analyst consensus. Piper Sandler also increased its price target for BMY to USD 82.00, citing pipeline milestones, while the company maintains a quarterly dividend of USD 0.63 per share.
Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
Pfizer is showing strong potential for a significant turnaround, with 24/7 Wall St. rating it a BUY with a $33 price target, implying a 20% upside from its current $27.60 share price. The company has delivered ten consecutive earnings beats, and its pipeline, particularly the Metsera GLP-1 deal for obesity and advancements in oncology, is expected to drive future growth despite a shrinking COVID-related revenue. Investors are encouraged by Pfizer's valuation at 10x forward earnings and a 6% dividend yield, positioning it as a value play among its peers.
ADVERTISEMENT by Bristol-Myers Squibb — The Part of the Story Oncologists Rarely Get to Hear
Monica Shaw, M.D., Senior Vice President at Bristol Myers Squibb, highlights a campaign called "Time Back" that aims to show oncologists the post-treatment lives of their patients. The initiative collects stories of ordinary moments patients experience after successful treatment, emphasizing that these moments are the true measure of progress in cancer care. The campaign seeks to bridge the gap between the difficult conversations oncologists have and the fulfilling lives their work helps make possible.
NOVARTIS AG N (NOTA.F) Q2 FY2026 earnings call transcript
Novartis reported strong Q2 FY2026 performance, with net sales up 1% and core operating income flat, driven by key growth brands like KISQALI, Cosentyx, and Scemblix. The company reaffirmed its full-year 2026 guidance, expecting low single-digit net sales growth and a low single-digit decline in core operating income. Novartis highlighted significant pipeline advancements, including updated KISQALI data, progress in rare disease programs like del-brax, and anticipated regulatory milestones and readouts for various assets in the second half of the year.
Bristol Myers Squibb stock faces a key October 29 results date
Bristol Myers Squibb (BMY) stock closed at $61.15 on October 2, 2026, 10.9% below its 52-week high, as the company approaches its Q3 2026 earnings release on October 29, 2026. The Q2 revenue was $12.97 billion, exceeding estimates, and analysts have a "Moderate Buy" consensus with an average 12-month price target of $67.06. The upcoming results will be crucial for the stock, balancing new medicine progress against patent expirations.
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
This article compares AbbVie (ABBV) and Bristol Myers (BMY), two pharmaceutical companies that have recently navigated or are about to navigate patent expirations. While AbbVie successfully replaced its blockbuster drug Humira with Skyrizi and Rinvoq, showing strong growth and operating margins, Bristol Myers is highlighted as a cheaper stock with better net margins and return on equity, despite facing its own upcoming patent cliff. The analysis concludes that AbbVie is the better business, but Bristol Myers is the better-priced stock, offering a higher yield and lower forward multiple.
Eli Lilly & Co (LLY) Gets a Buy from RBC Capital
RBC Capital analyst Trung Huynh maintained a Buy rating on Eli Lilly & Co (LLY) with a price target of $1,500.00, following the company's strong Q2 earnings report. Another firm, TD Cowen, also reiterated a Buy rating with a $1,250.00 price target. The analyst consensus for Eli Lilly & Co is a Strong Buy, with a collective price target suggesting an 18.64% upside.
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY), two pharmaceutical companies that have both faced the challenge of replacing blockbuster drugs. While AbbVie has successfully replaced Humira and shows stronger operational growth, Bristol Myers is presented as the better-priced stock, trading at a lower multiple with higher net margins and dividend yield. The analysis concludes that while AbbVie is a better business, Bristol Myers offers a more attractive investment at its current valuation.
After acquiring 620.994 deferred stock units, Rice holds 42,084.867 at Bristol Myers Squibb (BMY).
Bristol Myers Squibb director Derica W. Rice acquired 620.994 Deferred Share Units on September 30, 2026. This transaction increased her direct balance to 42,084.867 Deferred Share Units, which include deferred compensation and reinvested dividends. These units will convert to common stock when she ceases to be a director or on a pre-specified future date.
Exelixis, Inc. (EXEL) stock price, news, quote and history
This article provides a detailed overview of Exelixis, Inc. (EXEL), an oncology company. It includes current stock performance, key financial data such as market cap and P/E ratio, and an overview of its drug pipeline and collaborations. The company's historical performance, earnings trends, and analyst insights are also presented.
CX Institutional Sells 208,135 Shares of Bristol Myers Squibb Company $BMY
CX Institutional significantly reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 79.0% in the third quarter, selling 208,135 shares and leaving them with 55,461 shares valued at $3.46 million. This reduction comes amidst other institutional investors either buying or increasing their positions in the biopharmaceutical company. The article also provides details on analyst ratings, recent price performance, financial metrics, and upcoming dividend information for Bristol Myers Squibb.
Nancy Freda Smith Files Initial SEC Ownership Disclosure as New Director of Tempest Therapeutics
Nancy Freda Smith, newly appointed Director of Tempest Therapeutics, Inc. (NASDAQ:TPST), has filed her initial SEC Statement of Beneficial Ownership (Form 3). The filing, dated October 2, 2026, and effective September 22, 2026, indicates that Smith holds no beneficial ownership of any securities in the company. This disclosure is a standard procedure for new directors.
Comcast Director Gordon Smith Purchases 1,552 Shares of Class A Stock
Comcast Director Gordon Smith acquired 1,552 shares of Class A Common Stock on September 30, 2026, according to a Form 4 filed with the SEC on October 2, 2026. The acquisition was noted at a price of $0.0000 per share, increasing his direct holdings to 12,221.253 shares. The filing was signed by Elizabeth Wideman as attorney-in-fact, and did not confirm the presence of a Rule 10b5-1 trading plan.
AbbVie joins US government pilot to test drug discount rebates
AbbVie will participate in a US government pilot program to test a new rebate system for discounted medicines under the 340B program, starting January 1, 2027. This initiative aims to improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect. Other major pharmaceutical companies like Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also part of this federal pilot.
AbbVie joins US government pilot to test drug discount rebates
AbbVie will participate in a U.S. government pilot program starting January 1, 2027, to test a new rebate system for discounted medicines under the 340B program. This initiative aims to improve pricing transparency and prevent duplicate discounts for drugs like Imbruvica, Linzess, and Vraylar, especially as new Medicare-negotiated drug prices take effect. Other major pharmaceutical companies like Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also approved for this federal pilot.
SDGR Stock: Schrödinger Hopes Its AI Agent Can Transform Drug Discovery
Schrödinger (SDGR) leverages its physics-based software platform, molecular simulation, machine learning, and AI to transform drug discovery and materials science. The company's recent Q2 2026 results highlighted a strategic shift towards hosted software, the launch of its agentic AI product Bunsen, and significant drug discovery revenue driven by a milestone from Eli Lilly's acquisition of Ajax Therapeutics. Bunsen, designed as an AI co-scientist, is expected to be a major growth driver, with a strategic agreement already signed with Bristol Myers Squibb.
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
BMO Capital Markets is more optimistic about Merck's strategy to offset the upcoming patent cliff for Keytruda than it is about Bristol Myers Squibb's efforts to replace lost revenue from Opdivo and Eliquis. Merck has prepared a strong pipeline of growth products, including an mRNA cancer vaccine, Winrevair, and sac-TMT, which are expected to generate significant sales. In contrast, BMS's replacement assets, such as Cobenfy and milvexian, are considered riskier and have faced challenges, making BMO less confident in BMS's ability to stabilize revenue.
What Does Bristol Myers Squibb (BMY) Gain From Its Broader Heart Drug Approval?
Bristol-Myers Squibb received FDA approval for an expanded indication of its heart drug CAMZYOS, now covering both adult and pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This makes CAMZYOS the first FDA-approved oHCM therapy for children and gives it the broadest indication among cardiac myosin inhibitors. The approval supports the company's strategy of growing its cardiovascular portfolio to offset pressures on older drugs, but investors should also consider risks like pricing and safety.
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Agios Pharmaceuticals is heavily relying on its lead therapy, mitapivat, for commercial growth as it expands into multiple blood disorders, including pyruvate kinase deficiency and thalassemia, and seeks approval for sickle cell disease. Despite strong early commercial performance for Pyrukynd and Aqvesme, the company faces significant competition from other pharmaceutical giants like Novo Nordisk and Bristol Myers Squibb in its target markets. The discontinuation of a next-generation growth driver, tebapivat, further underscores mitapivat's critical role in Agios's near-to-medium-term success.
Sanofi, Regeneron broaden alliance to find their next Dupixent
Sanofi and Regeneron have expanded their long-standing alliance with a $1 billion upfront payment to develop new long-acting antibody drugs, targeting the same interleukins as their blockbuster Dupixent. This collaboration aims to create "next-generation" immunology medicines, addressing concerns about Dupixent's upcoming patent expirations and potentially setting the stage for future partnerships. While the deal is seen as positive for Regeneron, the new drugs are still in early development, and their differentiation in a crowded market remains to be proven.
AbbVie vs. Bristol Myers Squibb: A Clash Between Growth Premium and Value Trap
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY), highlighting the dilemma investors face between AbbVie's growth premium and Bristol Myers' perceived value trap. AbbVie shows strong revenue growth driven by immunology but has a high valuation, while Bristol Myers Squibb, despite a lower valuation, faces legal challenges and patent expiry risks. The article examines their financial profiles, risks, and outlooks for 2026, suggesting AbbVie is a better long-term investment even at a premium.
RBC Capital Remains a Hold on Novartis AG (NOVN)
RBC Capital analyst Trung Huynh has maintained a Hold rating on Novartis AG (NOVN) with a price target of CHF120.00. This aligns with the Street's general consensus, suggesting a Hold rating for Novartis AG with an average price target of CHF124.92. The company recently reported quarterly revenues of CHF14.16 billion and a net profit of CHF3.21 billion for the quarter ending June 30.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY) as investment options for 2026, highlighting their financial profiles, growth drivers, and risk factors. AbbVie is seen as a higher-growth stock with new immunology drugs, while Bristol Myers Squibb offers a significant valuation discount but faces litigation and patent expiration challenges. The author recommends AbbVie for long-term investors despite its higher price, anticipating strong growth in net income.
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale
This article compares the quarterly revenue scale of Bristol-Myers Squibb (BMY) and Johnson & Johnson (JNJ), highlighting JNJ's significantly larger revenue base and impressive growth rate. While BMY shows steady growth in biopharmaceuticals, JNJ's diversified healthcare business, including its medical technology division, provides a broader scope for expansion. The report details recent corporate activities and quarterly revenue figures for both companies, suggesting JNJ's medical technology segment is a key area for future growth.
Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from JonesTrading
JonesTrading analyst Debanjana Chatterjee maintained a Buy rating for Contineum Therapeutics, Inc. Class A (CTNM) with a price target of $26.00. This follows a previous Buy rating from Stifel Nicolaus's Paul Matteis, although Morgan Stanley assigned a Hold rating. The company reported a GAAP net loss of $15.15 million for the quarter ending June 30.
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
Cantor Fitzgerald reiterated an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) after the biotech company released additional one-year data from its Phase 1/2 ACHIEVE study for DM1 patients. Despite a 17% year-to-date stock decline, shares are up 28% over the past year. The company's financial position is strong, with more cash than debt, as it progresses towards regulatory milestones, though some analysts have adjusted price targets due to Novartis's recent trial failure in a similar study.
Pfizer’s Phase II Atopic Dermatitis Data Push Tilrekimig Into Pivotal AD, Asthma Trials
Pfizer is advancing its trispecific drug, tilrekimig, into pivotal Phase III trials for atopic dermatitis and asthma, following positive Phase II data. The company is also conducting a Phase IIb/III study for tilrekimig in COPD, aiming to assess the efficacy of targeting three pathways simultaneously. This move signifies Pfizer's renewed efforts in the atopic dermatitis space and its broader strategy for immune and respiratory disorders.
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients
The FDA has approved Bristol Myers Squibb’s CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult and pediatric patients weighing 30 kg or more. This expanded indication makes CAMZYOS the broadest-indicated cardiac myosin inhibitor and provides a new treatment option for a serious cardiovascular disease. The approval is supported by positive results from the Phase 3 SCOUT-HCM trial in pediatric patients, showing significant reduction in LVOT gradient, and builds on extensive clinical evidence from adult studies.
What You Could Reuse From Bristol Myers Squibb's 46% Gain
Bristol-Myers Squibb (NYSE: BMY) saw a 46.1% return for shareholders over the past year, despite ongoing concerns about patent cliffs and debt. The article highlights two investor narratives—optimistic and pessimistic—that existed a year ago, focusing on revenue, profit margins, and P/E ratios. Recent Q2 2026 results showed strong net income growth, pushing the company closer to the optimistic outlook, though patent issues and litigation remain a factor.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Bristol Myers Squibb and Eli Lilly and Co. as healthcare stock investments for 2026, highlighting their differing investment profiles. Bristol Myers Squibb is presented as a deep-value dividend payer with an established but maturing portfolio, facing patent expirations and regulatory pressures. Eli Lilly is depicted as a high-growth pharmaceutical company driven by breakthroughs in metabolic treatments like GLP-1 drugs, with strong revenue growth and a more conservative debt profile. The author ultimately recommends Eli Lilly due to its significant growth potential and innovative pipeline.
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
The article analyzes the Q2 earnings performance of pharmaceuticals stocks, highlighting Jazz Pharmaceuticals (NASDAQ:JAZZ) as a strong performer with revenues up 15.5% year-on-year, though its stock price dipped post-earnings. Bristol-Myers Squibb (NYSE:BMY) also had an impressive quarter, while Zoetis (NYSE:ZTS) was the weakest performer with flat revenues and missed expectations. The pharmaceuticals sector as a whole reported strong Q2 results, with revenues beating estimates by 5.5%.
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
Bristol Myers Squibb has altered its late-stage trial for the pulmonary fibrosis drug admilparant due to liver-related safety events, including one patient death. While the company and analysts suggest the safety concerns might be "overdone" and not necessarily drug-related, the revisions have reignited historical concerns about liver toxicity within the LPA1R inhibitor drug class. The trial's results, expected by year-end, are highly anticipated to clarify the safety profile of admilparant and similar drugs.
PFE vs. BMY: Each Faces a $22 Billion+ Patent Cliff. One Dividend Looks Much Safer
Both Pfizer (PFE) and Bristol Myers Squibb (BMY) are facing significant patent cliffs by 2028, with over $22 billion in revenue each from drugs losing exclusivity, including their shared drug Eliquis. While Pfizer offers a higher yield of 6% compared to Bristol Myers' 4%, Bristol Myers' dividend appears safer due to a comfortable 45% cash dividend payout ratio against Pfizer's risky 89%. Bristol Myers also has a 17-year streak of dividend increases, unlike Pfizer whose dividend has been flat since early 2025, despite Pfizer's management assuring dividend maintenance.
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Moderna (MRNA) and BioNTech (BNTX), both prominent in mRNA technology, are transitioning from COVID-19 vaccine reliance to developing new therapies. Moderna appears to be further along in this diversification, with approved respiratory vaccines and positive late-stage oncology results. BioNTech, while having a broader oncology pipeline, faces greater challenges with revenue replacement as COVID-19 vaccine demand normalizes and has experienced recent clinical setbacks.
This Pharma Giant Has The Right Medicine For Income Investors
Bristol Myers Squibb (BMY) is presented as a strong option for income investors seeking high yield and stable fundamentals in the healthcare sector. The pharmaceutical giant, based in Princeton, N.J., develops medicines for serious diseases and boasts a deep pipeline of 49 compounds. This extensive portfolio distinguishes it from smaller drugmakers that are often dependent on the success of only one or two products.
Does Pfizer (PFE) Look Fairly Valued As Cancer Data Builds?
Pfizer's stock, currently trading at US$28.72, has seen a 20.6% return over the past year. The company's P/E ratio of 37.7x is above the broader pharmaceuticals sector average but below a peer group average, suggesting it might be overvalued based on current earnings. Recent oncology data and late-stage cancer drug candidates are key factors influencing its future profitability and valuation, with community narratives offering both bullish and bearish perspectives on its fair value.
Top 10: Bio-Pharmaceutical Companies
Healthcare Digital has compiled a ranking of the top 10 bio-pharmaceutical companies based on the size of their R&D pipelines, utilizing data from Citeline’s 2026 Pharma R&D Annual Review. The article highlights the extensive drug development efforts of these leading firms, ranging from established industry giants like AstraZeneca and Roche to growing players such as Jiangsu Hengrui Pharmaceuticals, showcasing their contributions to shaping the future of medicine. Each company's profile includes details on their R&D pipeline size, number of employees, key therapeutic areas, and strategic acquisitions, illustrating their impact on the global biopharmaceutical landscape.
Takeda details Phase 3 psoriasis comparison with Sotyktu
Takeda Pharmaceutical Company Limited announced detailed Phase 3 results for its psoriasis drug, zasocitinib, showing superior complete skin clearance compared to Bristol Myers Squibb's Sotyktu (deucravacitinib). The LATITUDE Atlas study demonstrated that 36.5% of zasocitinib patients achieved PASI 100 at week 16, significantly outperforming deucravacitinib's 13.9%. Takeda's New Drug Application for zasocitinib has received priority review from the FDA, with a target action date in Q1 2027.
Neurocrine Biosciences Welcomes Back Eiry Roberts as Chief Medical Officer
Neurocrine Biosciences has reappointed Eiry Roberts, MD, as Chief Medical Officer, a position she previously held from 2018 to 2025. During her prior tenure, Roberts played a key role in the development and FDA approval of Ingrezza and Crenessity. Her return is expected to provide continuity and advance the company's clinical development programs.
Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth.
The global computer-aided drug discovery (CADD) market is projected to grow from $3.2 billion in 2025 to $6.7 billion by 2032, driven by an 11% CAGR. This growth is fueled by advancements in AI, machine learning, cloud computing, and multi-omics, which are accelerating drug discovery, reducing costs, and enabling personalized therapies. The report details market trends, growth drivers, and segmented forecasts, highlighting key players like Bayer and Charles River Laboratories.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Bristol Myers Squibb (BMY) and Eli Lilly (LLY), two major healthcare stocks, to determine which is a better investment in 2026. BMY is presented as a deep-value dividend payer with a maturing drug portfolio and strong free cash flow, while LLY is characterized as a high-growth pharmaceutical juggernaut driven by its metabolic and weight-loss treatments. The analysis concludes that despite BMY's lower valuation, LLY's explosive growth potential from its GLP-1 drugs makes it the more attractive buy.
Freeport-McMoRan (NYSE:FCX) Stock Falls 1.7% - Here's What Happened
Freeport-McMoRan (NYSE:FCX) shares dropped 1.7% on Tuesday, trading at $70.7260 with significantly lower than average volume. Despite the dip, analysts maintain a "Moderate Buy" consensus rating and an average price target of $71.35. The company recently surpassed earnings and revenue expectations, reporting $0.74 EPS and $7.03 billion in revenue, and declared a quarterly dividend of $0.075.
Potential liver safety issue seen in phase 3 trial for Bristol's admilparant
A potential liver safety issue has been identified in the phase 3 EU trial protocols for Bristol Myers Squibb's investigational drug, admilparant. The drug is currently being studied for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. This issue was noted in a recently amended long-term extension protocol for the trial.
AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug
AstraZeneca is making a $2 billion equity investment in Summit Therapeutics, signaling a research collaboration focused on combining drugs for gastrointestinal cancers. The deal highlights AstraZeneca's interest in ivonescimab, Summit's bispecific antibody, and its potential in combination with AstraZeneca's own antibody-drug conjugates (ADCs) to overcome drug resistance in cancer treatment. This collaboration underscores a growing trend in the pharmaceutical industry to explore novel drug pairings for enhanced oncology outcomes.
Morgan Stanley Plans Dallas Hub With $684 Million Expansion
Morgan Stanley Services Group Inc. is establishing a new U.S. operations hub in Dallas, investing $684 million and creating over 3,800 jobs. The state of Texas is providing nearly $43.9 million in incentives, including a Texas Enterprise Fund grant, to support this expansion. This move further solidifies Texas's reputation as a growing financial capital, attracting major companies and strengthening Dallas's financial sector.
Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?
Bristol-Myers Squibb (BMY) has reported positive Phase 3 EXCALIBER-RRMM results for its drug ZENBEXUS in relapsed or refractory multiple myeloma, showing a significant improvement in treatment response. This data strengthens the company's oncology portfolio and supports its regulatory and commercial strategies, particularly as it aims to offset patent pressures on existing blockbuster drugs. Investors are advised to monitor future regulatory updates and usage trends for ZENBEXUS to gauge its market traction.
Cytokinetics CEO Robert Blum sells $490,949 in stock By Investing.com
Cytokinetics CEO Robert Blum sold 7,500 shares of company common stock worth $490,949 after exercising non-qualified stock options. Following the transactions, Blum directly holds 278,544 shares and 149,245 derivative securities. This comes amidst positive analyst revisions for earnings and strong sales for the company's drug Myqorzo.
Summit soars after $2 billion investment from AstraZeneca for cancer therapies
Summit Therapeutics' shares surged after AstraZeneca announced a $2 billion investment to jointly test cancer treatments. This deal provides Summit with a significant cash infusion and strategic options, while giving AstraZeneca access to Summit's promising ivonescimab, a new cancer treatment mechanism. Both companies will retain rights to their respective molecules and plan further clinical trials combining their cancer medicines.
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE)
Pfizer is recommended as a Buy due to its strong growth portfolio and significant cost-restructuring initiatives, despite near-term challenges from COVID-19 revenue normalization and patent expirations. The company's new and acquired products are driving double-digit growth, while planned savings of $9.7 billion by 2029 are expected to bolster earnings and margins. A 6% dividend yield and deep-value multiple provide investor support for medium- to long-term upside.
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
Novo Nordisk is set to acquire ex-China rights to Hengrui Pharma's preclinical GLP-1/GIP dual receptor agonist, HRS-1596, for an upfront payment of $300 million and potential milestone payments up to $2.6 billion. The drug, designed for once-weekly oral dosing, aims to treat obesity, Type 2 diabetes, and other metabolic diseases, offering a potentially more convenient alternative to existing treatments. This deal is part of Novo's strategy to strengthen its pipeline and address investor concerns following recent challenges.
